Gemcitabine in metastatic breast cancer

Expert Review of Anticancer Therapy

Volumn 5, Issue 3, 2005, Pages 429-443

  Heinemann, Volker ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Breast cancer; Gemcitabine; Metastatic

Indexed keywords

ANALGESIC AGENT; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC ANTIMETABOLITE; CAPECITABINE; CISPLATIN; CYCLOPHOSPHAMIDE; DNA; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; HEMOPOIETIC GROWTH FACTOR; MITOXANTRONE; NAVELBINE; PACLITAXEL; PYRIMIDINE DERIVATIVE; TRASTUZUMAB;

ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; BACKACHE; BREAST CANCER; BREAST SURGERY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PAIN; CANCER REGRESSION; CANCER SURVIVAL; CHILL; CLINICAL TRIAL; CYTOTOXICITY; DISEASE COURSE; DNA REPAIR; DNA STRAND BREAKAGE; DRUG CLEARANCE; DRUG EXCRETION; DRUG FATALITY; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FLU LIKE SYNDROME; GASTROINTESTINAL DISEASE; HEADACHE; HEART DISEASE; HEMATOLOGIC DISEASE; HUMAN; INHIBITION KINETICS; LACRIMAL GLAND DISEASE; LUNG DISEASE; META ANALYSIS; METASTASIS POTENTIAL; MONOTHERAPY; MYALGIA; NAIL DISEASE; NAUSEA AND VOMITING; NEUROLOGIC DISEASE; NEUTROPENIA; PERIPHERAL EDEMA; PREOPERATIVE CARE; QUALITY OF LIFE; RELIABILITY; SKIN DISEASE; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TIME; TREATMENT FAILURE; TREATMENT OUTCOME;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DEOXYCYTIDINE; DNA DAMAGE; DNA REPAIR; FEMALE; HUMANS; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME;

EID: 21244462774     PISSN: 14737140     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737140.5.3.429     Document Type: Article

References (102)

1. Nabholtz JMA, Reese DM, Lindsay MA et al. Combination chemotherapy for metastatic breast cancer. Expert Rev. Anticancer Ther. 2, 169-180 (2002).
2. Sledge GW, Neuberg D, Bernardo P et al. Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J. Clin. Oncol. 21, 588-592 (2003).
3. Heinemann V, Hertel LW, Grindey GB, Plunkett W. Comparison of the cellular pharmacokinetics and toxicity of 2′,2′-difluorodeoxycytidine and 1-β-D-arabinofuranosylcytosine. Cancer Res. 48, 4024-4031 (1988).
4. Huang P, Chubb S, Hertel LW et al. Action of 2′,2′-difluorodeoxycytidine on DNA synthesis. Cancer Res. 51, 6110-6117 (1991).
5. Heinemann V, Xu YZ, Chubb S et al. Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2′,2′-difluorodeoxycytidine. Mol. Pharmacol. 38, 567-572 (1990).
6. Robinson BW, Ostruszka L, IM MM et al. Promising combination therapies with gemcitabine. Semin. Oncol. 31(2 Suppl. 5), 2-12 (2004).
7. Plunkett W, Huang P, Searcy CE, Gandhi V. Gemcitabine: Pharmacology and mechanisms of action. Semin. Oncol. 23(5 Suppl. 10), 3-15 (1996).
8. Achiwa H, Oguri T, Sato S, Maeda H, Niimi T, Ueda R. Determinants of sensitivity and resistance to gemcitabine: the roles of human equilibrative nucleoside transporter 1 and deoxycytidine kinase in non-small cell lung cancer. Cancer Sci. 95, 753-757 (2004).
9. Kroep JR, Loves WJ, van der Wilt CL et al. Pretreatment deoxycytidine kinase levels predict in vivo gemcitabine sensitivity. Mol. Cancer Ther. 1, 371-376 (2002).
10. Davidson JD, Ma L, Flagella M et al. Increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines. Cancer Res. 64, 3761-3766 (2004).
11. Tolis C, Peters GJ, Ferreira CG et al. Cell cycle disturbances and apoptosis induced by topotecan and gemcitabine on human lung cancer cell lines. Eur. J. Cancer 35, 796-807 (1999).
12. Galmarini CM, Clarke ML, Falette N et al. Expression of a non-functional p53 affects the sensitivity of cancer cells to gemcitabine. Int. J. Cancer 97, 439-445 (2002).
13. Storniolo AM, Allerheiligen SR, Pearce HL. Preclinical, pharmacologic and Phase I studies of gemcitabine. Semin. Oncol. 24(2 Suppl. 7), S2-S7 (1997).
14. Green MR. Gemcitabine safety overview. Semin. Oncol. 23(5 Suppl. 10), 32-35 (1996).
15. Blackstein M, Vogel CL, Ambinder R et al. Gemicitabine as first line therapy in patients with metastatic breast cancer: a Phase II trial. Oncology 62(1), 2-8 (2001).
16. Possinger K, Kaufmann M, Coleman R et al. Phase II study of gemcitabine as first-line chemotherapy in patients with advanced or metastatic breast cancer. Anticancer Drugs 10(2), 155-162 (1999).
17. Feher O, Vodvarka P, Jassem J et al. Randomized Phase III study of epirubicin 7versus gemcitabine chemotherapy in elderly females with metastatic breast cancer. European J. Cancer 38(Suppl. 3), S66 (2002).
18. Carmichael J, Possinger K, Phillip P et al. Advanced breast cancer: a Phase II trial with gemcitabine. J. Clin. Oncol. 13(11), 2731-2736. (1995).
19. Valerio MR, Cicero G, Armata MG et al. Gemcitabine (G) in pretreated breast cancer (BC). Proc. Am. Soc. Clin. Oncol. 20, 51b (2001).
20. Brodowicz T, Kostler WJ, Moslinger R et al. Single-agent gemcitabine as second- and third-line treatment in metastatic breast cancer. The Breast 9, 338-342 (2000).
21. Gerson R, Serrano-O A, Villalobos A et al. Gemcitabine response in advanced breast cancer in relation to immunohistochemical factors. Proc. Am. Soc. Clin. Oncol. 19, 145a (2000).
22. Spielmann M, Llombart-Cussac A, Kalla S et al. Single-agent gemcitabine is active in previously treated metastatic breast cancer. Oncology 60, 303-307 (2001).
23. Smorenburg CH, Bontenbal M, Seynaeve C et al. Phase II study of weekly gemcitabine in patients with metastatic breast cancer relapsing or failing both an anthracycline and a taxane. Breast Cancer Res. Treat. 66, 83-87 (2001).
24. Schmid P, Akrivakis K, Flath B et al. Phase II trial of gemcitabine as prolonged infusion in metastatic breast cancer. Anticancer Drugs 10, 625-31 (1999).
25. Carmichael J, Walling J. Phase II activity of gemcitabine in advanced breast cancer. Semin. Oncol. 23(5 Suppl. 10), 77-81 (1996).
26. Kaklamani VG, Gradishar WJ. Role of capecitabine (Xeloda®) in breast cancer. Expert Rev. Anticancer Ther 3, 137-144 (2003).
27. Jones S, Winer E, Vogel C et al. Randomized comparison of vinorelbine and melphalan in anthracycline-refractory advanced breast cancer. J. Clin. Oncol. 13(10), 2567-2574 (1995).
28. Zelek L, Barthier S, Riofrio M et al. Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast cancer. Cancer 92, 2267-2272 (2001)
29. Kroep J R, Tolis C, Voorn DA et al. Sequence dependent effect of paclitaxel on gemcitabine metabolism in relation to cell cycle and cytotoxicity in non-small-cell lung cancer cell lines. Br. J. Cancer 83, 1069-1076 (2000).
30. Holmes FA, Valero V, Walters et al. The M.D. Anderson Cancer Center experience with Taxol in metastatic breast cancer. J. Natl Cancer. Inst. Monogr. 15, 161-169 (1993).
31. Clemons M, Leahy M, Valle J et al. Review of recent trials of chemotherapy for advanced breast cancer: the taxanes. Eur. J. Cancer 33, 2183-2193 (1997).
32. Seidman AD, Reichman BS, Crown JPA et al. Paclitaxel as second and subsequent therapy for metastatic breast cancer: activity independent of prior anthracycline responsc. J. Clin. Oncol. 13, 1152-1159 (1995).
33. Abrams JS, Vena DA, Baltz J et al. Paclitaxel activity in heavily pretreated breast cancer: a National Cancer Institute treatment referral center trial. J. Clin. Oncol. 13, 2056-2065 (1995).
34. Nabholtz JM, Gelmon K, Bontenbal M et al. Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J. Clin. Oncol. 14, 1858-1867 (1996).
35. Delfino C, Caccia G, Riva Gonzales L et al. Gemcitabine plus paclitaxel as first-line chemotherapy for patients with advances breast cancer. Oncology 66, 18-23 (2004).
36. Colomer R, Llombart A, Lluch A et al. Paclitaxel/gemcitabine administered every two weeks in advanced breast cancer: preliminary results of a Phase II trial. Semin. Oncol. 27(1 Suppl. 2), 20-24 (2000).
37. Genot JY, Tubiana-Hulin M, Tubiana-Mathiew N et al. Gemcitabine and paclitaxel in metastatic breast cancer: a Phase II study in the first line setting. Proc. Am. Soc. Clin. Oncol. 21, 53b (2002) (Abstract 2025).
38. Sanchez P, Medina MB, Mohedano N et al. Results from a Phase II study of gemcitabine in combination with paclitaxel in metastatic breast cancer. Ann. Oncol. (1998) (Abstract 77P).
39. Murad AM, Guimaraes RC, Aragao BC et al. Phase II trial of the use of paclitaxel and gemcitabine as a salvage treatment in metastatic breast cancer. Am. J. Clin. Oncol. 24(3), 264-268 (2001).
40. Paridaens R, Biganzoli L, Bruning P et al. Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: A European Organization for Research and Treatment of Cancer randomized study with cross-over. J. Clin. Oncol. 18 (4), 724-733 (2000).
41. Khoo KS, Zaidi M, Srimuninnimit V et al. Randomized Phase II trial of three gemcitabine-taxane combinations in metastatic breast cancer. J. Clin. Oncol. 22 (Suppl. 15), S14 (2004) (Abstract 710).
42. O'Shaughnessy J, Nag S, Calderillo-Ruiz et al. Gemcitabine plus paclitaxel versus paclitaxel as first-line treatment for anthracycline pre-treated metastatic breast cancer: interim results of a global Phase II study. Proc. Am. Soc. Clin. Oncol. 22, 7 (2003) (Abstract 25).
43. Albain KS, Nag S, Calderillo-Ruiz et al. Global Phase III study of gemcitabine plus paclitaxel versus paclitaxel as frontline therapy of metastatic breast cancer: first report of overall survival. Proc. Am. Soc. Clin. Oncol. 23, 5 (2004) (Abstract 510).
44. Moinpur C, Wu J, Donaldson G et al. Gemcitabine plus paclitaxel versus paclitaxel as first-line treatment for anthracycline pre-treated metastatic breast cancer : quality of life and pain palliation results from the global Phase III study. Proc. Am. Soc. Clin. Oncol. 23, 32 (2004) (Abstract 621).
45. Valero V. Docetaxel as single-agent therapy in metastatic breast cancer: clinical efficacy. Semin. Oncol. 24(S13), 11-18 (1997).
46. Cortes JH, Pazdur R. Docetaxel. J. Clin. Oncol 13, 2643-2655 (1995).
47. Burris HA. Single-agent docetaxel (Taxotere®) in randomized Phase III trials. Semin. Oncol. 26(3 Suppl. 9), 1-6 (1999).
48. Alexopoulos A, Kandilis K, Stavrakakis J et al. Evidence for in vivo synergism between docetaxel and gemcitabine in patients with metastatic cancer. Ann. Oncol. 15, 95-99 (2004).
49. Pelegri A, Calvo L, Mayordomo JI et al. Gemcitabine plus docetaxel administered every other week as first-line treatment of metastatic breast cancer: preliminary results from a Phase II trial. Semin. Oncol. 31(2 Suppl. 5), 20-24 (2004).
50. Mavroudis D, Malamos N, Polyzos A et al. Front-line chemotherapy with docetaxel and gemcitabine administered every two weeks in patients with metastatic breast cancer: a multicenter Phase II study. Oncology 67, 250-256 (2004).
51. Garle PA, Calvo L, Mayordomo JI et al. Gemcitabine and docetaxel given every other week as first-line therapy for metastatic breast cancer: final results of a Phase II study conducted within the Breast Cancer Investigation Spanish Group (GEICAM). Proc. Am. Soc. Clin. Oncol. 22, 50 (2003) (Abstract 201).
52. Laufman LR, Spiridonidis CH, Pritchard J et al. Monthly docetaxel and weekly gemcitabine in metastatic breast cancer: a Phase II trial. Ann. Oncol. 12, 1259-1264. (2001).
53. Kornek G, Raderer M, Fiebiger W et al. Treatment of advanced breast cancer (ABC) with docetaxel and gemcitabine with and without human granulocyte colony-stimulating factor. Clin. Cancer Res. 8, 1051-1056 (2002).
54. Brandi M, Vici P, Lopez M et al. Novel association with gemcitabine and docetaxel as salvage chemotherapy in metastatic breast cancer previously treated with anthracyclines: results of a multicenter Phase II study. Semin. Oncol. 31(2 Suppl. 5), 13-19 (2004).
55. Mavroudis D, Malamos N, Alexopoulos A et al. Salvage chemotherapy in anthracycline-pretreated metastatic breast cancer patients with docetaxel and gemcitabine: a multicenter Phase II trial. Greek Breast Cancer Cooperative Group. Ann. Oncol . 10(2), 211-215 (1999).
56. Fountzilas G, Nicolaide C, Bafaloukos day et al. Docetaxel and gemcitabine in anthracycline-resistant advanced breast cancer: a Hellenic Cooperative Oncology Group Phase II Study. Cancer Invest. 18, 503-509 (2000).
57. Gregory RK, Smith IE. Vinorelbine - a clinical review. Br. J. Cancer 82(12), 1907-1913 (2000).
58. Haider K, Kornek G V, Kwasny W et al. Treatment of advanced breast cancer with gemcitabine and vinorelbine plus human granulocyte colony-stimulating factor. Breast Cancer Res. Treat. 55, 203-211 (1999).
59. Valenza R, Leonardi V, Gebbia V, Agostara B. Gemcitabine and vinorelbine in pretreated advanced breast cancer: a pilot study. Ann. Oncol. 11, 495-496 (2000).
60. Stathopoulos GP, Rigotos SK, Pergantas N et al. Phase II trial of biweekly administration of vinorelbine and gemcitabine in pretreated advanced breast cancer. J. Clin. Oncol. 20, 37-41 (2002).
61. Nicolaides C, Dimopoulos MA, Samantas E et al. Gemcitabine and vinorelbine as second-line treatment in patients with metastatic breast cancer progressing after first-line taxane-based chemotherapy: a Phase II study conducted by the Hellenic Cooperative Oncology Group. Ann. Oncol. 11(7), 873-875 (2000).
62. Mariani G, Tagliabue P, Zucchinelli P et al. Phase I/II study of gemcitabine in association with vinorelbine for metastatic breast cancer. Breast Cancer Res. Treat. 70, 163-169 (2001).
63. Donadio M, Ritoro G, Novarino A et al. Phase II study of gemcitabine and vinorelbine in metastatic breast cancer. Ann. Oncol. 11 (Suppl. 4), 31 (2000) (Abstract 128p).
64. Moser R, Hausmaninger H, Mlineritsch B et al. Gemcitabine (G) and vinorelbine (V) as first or second line therapy in patients with advanced breast cancer (ABC) A prospective Phase II trial. Proc. Am. Soc. Clin. Oncol. 20, 56b (2001) (Abstract 1973).
65. Sanal AM, Gokmen E, Karabulut B et al. Gemcitabine and vinorelbine combination in patients with metastatic breast cancer. Breast J. 8, 171-176 (2002).
66. Hortobagyi GN. Gemcitabine in combination with vinorelbine for treatment of advanced breast cancer. Clin. Breast Cancer 3(Suppl. 1), S34-S38 (2002).
67. Sledge GW, Loeher PJ, Roth BJ et al. Cisplatin as first-line therapy for metastatic breast cancer. J. Clin. Oncol. 6, 1811-1814 (1988).
68. Kolaric K, Roth A. Phase II clinical trial of cis-dichlorodiamine platinum (cis-DDP) for antitumorigenic activity in previously untreated patients with metastatic breast cancer. Cancer Chemother. Pharmacol. 11, 108-112 (1983).
69. Heinemann V. Gemcitabine plus cisplatin for the treatment of metastatic breast cancer. Clin. Breast Cancer 3(Suppl. 1), S24-S29 (2002).
70. Decatris MP, Sundar S, O'Byrne KJ. Platinum-based chemotherapy in metastatic breast cancer: current status. Cancer Treat Rev. 4, 53-81 (2004).
71. Peters GJ, Bergman AM, Ruiz van Haperen VW et al. Interaction between cisplatin and gemcitabine in vitro and in vivo. Semin. Oncol. 22(4 Suppl. 11), 72-79 (1995).
72. Nagourney RA, Su YZ, Link J, DiSaia P, Evans SS. Gemcitabine synergy with cisplatin. Clinical and laboratory correlates. Proc. Am. Soc. Assoc. Cancer Res. 39, 310 (1998) (Abstract 2118).
73. Calderillo Ruíz GC, Fuentes de la Peña H, Meza FA et al. A Phase II study of gemcitabine plus cisplatin in metastatic breast cancer (MBC). Proc. Am. Soc. Clin. Oncol. 20, 60b (2001) (Abstract 1988).
74. Nagourney RA, Link JS, Blitzer JB et al. Gemcitabine plus cisplatin repeating doublet therapy in previously treated, relapsed breast cancer patients. J. Clin. Oncol. 18, 2245-2249 (2000).
75. Chaudry S, Abdel-Rahman HA, Patil R et al. Prospective Phase II study of weekly cisplatin-gemcitabine inrefractory metastatic breast cancer. Proc. Am. Soc. Clin. Oncol 19, 111a (2000) (Abstract 430).
76. Burch PA, Mailliard. JA, Hillman DW et al. Phase II study of gemcitabine and cisplatin in patients with metastatic breast cancer (MBC) and failure on prior chemotherapy: a North Central Cancer Treatment Group trial. Breast Cancer Res. Treat. 64, 81 (2000) (Abstract 322).
77. Galvez CA, Galmarini F, Curie M. Monthly cisplatin (C) and gemcitabine (G) as second line chemotherapy for patients with advanced breast cancer. Breast Cancer Res. Treat. 64, 81 (2000) (Abstract 324).
78. Shaharyar S, Alauddin Z, Rehman E et al. Gemcitabine and cisplatin combination chemotherapy as second-line treatment in patients with metastatic breast cancer. Proc. Am. Soc. Clin. Oncol. 22, 53 (2003) (Abstract 212).
79. Rahman ZU, Frye DK, Smith TL et al. Results and long-term follow-up for 1581 patients with metastatic breast carcinoma treated with standard dose doxorubicin-containing chemotherapy: a reference. Cancer 85, 104-111 (1999).
80. Perez-Manga G, Lluch A, Alba E et al. Gemcitabine in combination with doxorubicin in advanced breast cancer: Final results of a Phase II pharmacokinetic trial. J. Clin. Oncol. 18, 2545-2552 (2000).
81. Hausmaninger H, Morack G, Heinrich B et al. Gemcitabine combined with epirubicin in the treatment of patients with locally advanced or metastatic breast cancer. A Phase II study. Am. J. Clin. Oncol. 27, 429-435 (2004).
82. Silva A, Gonzalez H, Perez M et al. Neoadjuvant gemcitabine plus epirubicin in locally advanced breast cancer: evidence of activity in a Phase II study. Proc. Am. Soc. Clin. Oncol. 21, 51b (2002) (Abstract 2015).
83. Conte PF, Gennari A, Donati S et al. Gemcitabine plus epirubicin plus taxol (GET) in advanced breast cancer: a Phase II study. Breast Cancer Res. Treat. 68, 171-179 (2001).
84. Cappuzzo F, Mazzoni F, Gennari A et al. Multicentric Phase II trial of gemcitabine plus epirubicin plus paclitaxel as first-line chemotherapy in metastatic breast cancer. Br. J. Cancer 90, 31-35 (2004).
85. Sanchez-Rovira P, Jaen A, Gonzalez E et al. Biweekly gemcitabine, doxorubicin, and paclitaxel as first-line treatment in metastatic breast cancer: final results from a Phase II trial. Oncology 15(2 Suppl. 3), 44-47 (2001).
86. Zielinski C, Beslija S, Cervek J et al. Gemcitabine/epirubicin/paclitaxel (GET) vs 5-fluorouracil/epirubicin/ cyclophosphamide (FEC) as first-line treatment in metastatic breast cancer: interim toxicity analysis of a randomized, multicenter Phase III trial of the Central European Cooperative Oncology Group (CECOG). Proc. Am. Soc. Clin. Oncol. 20, 53b (2001) (Abstract 1958).
87. Kuerer HM, Newman LA, Smith TL et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J. Clin. Oncol. 17, 460-469 (1999).
88. Conte PF, Gennari A, Santoro A et al. Induction chermotherapy in operable breast cancer: a multicenter Italian Phase II study with the GET regimen. Proc. Am. Soc. Clin. Oncol. 22, 35 (2003) (Abstract 140).
89. Schneeweiss A, Huober J, Sinn HP et al. Gemcitabine, epirubicin and docetaxel as primary systemic therapy in patients with early breast cancer: results of a multicentre Phase I/II study. Eur. J. Cancer 40, 2432-2438 (2004).
90. Vogel CL, Cobleigh MA, Tripathy day et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J. Clin. Oncol. 20, 719-26 (2002).
91. Pegram MD, Konecny GE, O'Callaghan C et al. Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J. Natl Cancer Inst. 96, 739-49 (2004).
92. Hirsch FR, Helfrich B, Franklin WA et al. Preclinical studies of gemcitabine and trastuzumab in breast and lung cancer. Clin. Breast Cancer 3 (Suppl. 1), S12-S16 (2002).
93. Bunn PA Jr, Helfrich B, Soriano AF et al. Expression of Her-2/neu in human lung cancer cell lines by immunohistochemistry and fluorescence in situ hybridization and its relationship to in vitro cytotoxicity by trastuzumab and chemotherapeutic agents. Clin. Cancer Res. 7, 3239-3250 (2001).
94. Brufsky A, Orlando M, Fox K et al. Phase II study of gemcitabine and trastuzumab combination therapy in patients with HER2-overexpressing metastatic breast cancer. First stage results. Breast Cancer Res. Treat. 88(Suppl. 1), (2004) (Abstract 3047).
95. O'Shaughnessy J, Vukelja SJ, Marsland T et al. Phase II trial of gemcitabine plus trastuzumab in metastatic breast cancer patients previously treated with chemotherapy: preliminary results. Clin. Breast Cancer 3 (Suppl. 1), 17-20 (2002).
96. Chistodoulou C, Fountzilas G, Razi E et al. Gemcitabine and trastuzumab combination as salvage treatment in patients with HER-2-positive metastatic breast cancer. Proc. Am. Soc. Clin. Oncol. 22, 42 (2003) (Abstract 166).
97. Sledge GW. Gemcitabine, paclitaxel, and trastuzumab in metastatic breast cancer. Oncology 17(Suppl.), 33-35 (2003).
98. Colomer R, Mayordomo JI, Calvo L et al. HER2 ECD-positive metastatic breast cancer treated with gemcitabine, paclitaxel plud trastuzumab. Breast Cancer Res. Treat. 88(Suppl. 1) (2004) (Abstract 3046).
99. O'Shaughnessy J, Miles D, Vukelja S et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: Phase III trial results. J. Clin. Oncol. 15, 2812-2823 (2002).
100. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344, 783-792 (2000).
101. Tedesco KL, Thor AD, Johnson DH et al. Docetaxel combined with trastuzumab is an active regimen in HER-2 3+ overexpressing and fluorescent in situ hybridization-positive metastatic breast cancer: a multi-institutional Phase II trial. J. Clin. Oncol. 22, 1071-1077 (2004).
102. Burstein HJ, Harris LN, Marcom PK et al. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter Phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. J. Clin. Oncol. 21, 2889-2895 (2003).